ERRATUM

Busy panels recommend Pfizer's tofacitinib, Arena's lorcaserin and more

Asher Mullard

Nature Reviews Drug Discovery **11**, 429 (2012)

In the story 'Busy panels recommend Pfizer's tofacitinib, Arena's lorcaserin and more', the last sentence was incorrect. Johnson & Johnson's rivaroxaban is under review for acute coronary syndrome, not stroke prevention in atrial fibrillation. This has been corrected online.